Press releases – ASCELIA

All All press releases Regulatory press releases Financial reports

Regulatory

2020-12-15 | Ascelia Pharma gets US patent for second generation Mangoral

Regulatory

2020-12-02 | New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent

Regulatory

2020-11-05 | Quarterly Report Q3-2020: Raised market estimate for Mangoral and preparing for market launch

2020-11-03 | EMA confirms Mangoral eligible for the centralized regulatory procedure in the EU

Regulatory

2020-10-21 | Upgraded estimate of addressable market for Mangoral to $500-600 million annually

2020-09-30 | Invitation to Ascelia Pharma’s virtual Capital Markets Day

2020-09-18 | First commercial scale manufacturing of Mangoral

Regulatory

2020-08-20 | Quarterly Report Q2-2020: First participant in the hepatic study

Regulatory

2020-07-31 | Change in number of shares and votes in Ascelia Pharma AB

Regulatory

2020-06-30 | Ascelia Pharma completes a directed new share issue of 4,697,781 shares, raising approximately SEK 98.7 million

2020-06-09 | Presentation of Ascelia Pharma at ABGSC Life Science Summit Day and Redeye Orphan Drug Day

2020-05-26 | Vator Securities: Ascelia Pharma: A delay. Fundamentals for Mangoral remain unchanged.

Regulatory

2020-05-20 | Updated SPARKLE timelines due to Covid-19 impact

Regulatory

2020-05-13 | Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE

Regulatory

2020-05-06 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2020

Regulatory

2020-05-06 | First participant enrolled in the clinical hepatic impairment study with Mangoral

2020-04-16 | Patent for Oncoral approved in Japan

Regulatory

2020-04-06 | Ascelia Pharma publishes Annual Report for the financial year 2019